1. Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials. (2nd January 2022) Authors: Gordon, K. B.; Reich, K.; Crowley, J. J.; Korman, N. J.; Murphy, F. T.; Poulin, Y.; Spelman, L.; Yamauchi, P. S.; Mendelsohn, A. M.; Parno, J.; Rozzo, S. J.; Ellis, C. N. Journal: Journal of dermatological treatment Issue: Volume 33:Number 1(2022) Page Start: 219 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. THU0202 Five-Year Safety and Efficacy of Golimumab in Patients with Active Rheumatoid Arthritis Despite Previous Anti-Tumor Necrosis Factor Therapy: Final Study Results of the Phase 3, Randomized, Placebo-Controlled Go-After Trial. (23rd January 2014) Authors: Smolen, J. S.; Kay, J.; Landewé, R.; Matteson, E. L.; Gaylis, N.; Wollenhaupt, J.; Murphy, F. T.; Han, C.; Gathany, T.; Xu, S.; Zhou, Y.; Hsia, E. C.; Doyle, M. K. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A232 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗